• Publications
  • Influence
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy
We describe that galectin-1 (gal-1) is a receptor for the angiogenesis inhibitor anginex, and that the protein is crucial for tumor angiogenesis. gal-1 is overexpressed in endothelial cells ofExpand
Galectin expression in cancer diagnosis and prognosis: A systematic review.
Galectins are a family of proteins that bind to specific glycans thereby deciphering the information captured within the glycome. In the last two decades, several galectin family members have emergedExpand
The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells.
Endothelial cells express several members of the galectin family and that their expression and distribution changes on cell activation, resulting in a different profile in the tumor vasculature, which offers opportunities to develop therapeutic strategies that are independent of tumor type. Expand
The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
The concept of antiangiogenic therapy in cancer treatment has led to the approval of different agents, most of them targeting the well known vascular endothelial growth factor pathway. DespiteExpand
Expression of the smoothelin gene is mediated by alternative promoters.
Two major smoothelin isoforms are generated from a single gene by a dual promoter system in a tissue specific manner and it is shown that in vascular tissues a larger smoothelins transcript is generated than in visceral tissue. Expand
Antiangiogenesis therapy for endometriosis.
It is demonstrated that inhibitors of angiogenesis effectively interfere with the maintenance and growth of endometriosis by inhibiting angiogenic agents, suggesting that the use ofAngiostatic agents may be promising as a therapy for endometRIosis. Expand
Tumor cells secrete galectin-1 to enhance endothelial cell activity.
It is reported that tumors can stimulate tumor angiogenesis by secretion of galectin-1, which is identified as a proangiogenic factor and has direct implications for current efforts on galectIn-1-targeted cancer therapies. Expand
Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer
The expression levels of integrins alpha5, beta1 and beta3 predicted overall survival and disease free survival in early stage NSCLC patients and there was no association between integrin expression and lymph node metastases. Expand
MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard.
This review summarizes the available data of miRNA expression in the endothelium and describes the current knowledge regarding the function of miRNAs in endothelial cell biology and discusses the potential applications of mi RNA based treatment strategies in angiostatic cancer therapy. Expand
Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor
Cardioprotection resulting from the absence of HDAC5 or -9 in female mice can be attributed, at least in part, to enhanced neoangiogenesis in the infarcted region via upregulation of the ER target gene vascular endothelial growth factor-a. Expand